

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Lobel, et al.
SERIAL NO : 09/851,847 EXAMINER : Unassigned
FILED : May 9, 2001 ART UNIT : 1631
FOR : NOVEL HUMAN LYSOSOMAL PROTEIN AND METHODS OF ITS USE

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence (and any paper referred to as being transmitted herewith) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner of Patents, Washington, DC 20231 on September 11, 2002

Catherine Roseman Smith
(Name of depositor)

C R S 9/11/02
(Signature and Date)

Assistant Commissioner of Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References AA through AG listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement as it is being filed before the mailing of a first Office Action on the merits. However, should any fee be due, authorization is hereby given to charge the amount of such fee to Deposit Account No. 11-1153.

Respectfully submitted,

C R S
Catherine Roseman Smith
Attorney for Applicants
Registration No. 34,240

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800
September 11, 2002

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	601-1-077DIV
	SERIAL NO.	09/851,847
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Lobel, et al.
	FILING DATE	May 9, 2001
	GROUP	1631

U.S. PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Sharp, et al., Human Molecular Genetics, 1997, 6:591-595, Loci for classical and a variant late infantile neuronal ceroid lipofuscinosis map to chromosomes 11p15 and 15q21-23
	AB	Lerner, et al., Cell, 1995, 82:949-957, Isolation of a Novel Gene Underlying Batten Disease, CLN3.
	AC	Ivy, et al., American Journal of Medical Genetics, 1992, 42:555-560, Protease Inhibitors as a Model for NCL Disease, with Special Emphasis on the Infantile and Adult Forms.
	AD	Ashizawa, et al., American Journal of Medical Genetics, 1992, 42:55-60, Diagnostic Value of Ophthalmologic Finding in Myotonic Dystrophy: Comparison with Risks Calculated by Haplotype Analysis of Closely Linked Restriction Fragment Length Polymorphisms.
	AE	Sleat, et al., Biochem, 1997, 324:33-39, - Glucosidase and N-acetylglucosamine-6- sulphatase are the major mannose-6-phosphate glycoproteins in human urine.
	AF	Ezaki, et al., Journal of Neurochemistry, 1996, 67:1677-1687, Specific Delay in the degradation of Mitochondrial ATP Synthase Subunit c in Late Infantile Neuronal Ceroid Lipofuscinosis is Derived from Cellular Proteolytic Dysfunction rather than Structural Alteration of Subunit c.
	AG	Ivey, et al., Science, 1994, 226:985-987, Inhibitors of Lysosomal enzymes: Accumulation of Lipofuscin-Like Dense Bodies in the Brain
EXAMINER:		DATE CONSIDERED: